PMC

Mean change in 24-h, day-time and night-time ambulatory systolic blood pressure, body weight, in-office systolic blood pressure and glomerular filtration rate over the course of the study in placebo, dapagliflozin and hydrochlorothiazide groups. Data are reported as mean (± 95% CI). P, placebo; D,  dapagliflozin; H, hydrochlorothiazide.

Mean change in haematocrit, haemoglobin, reticulocyte count and erythropoietin over the course of the study in placebo dapagliflozin, and hydrochlorothiazide groups. Data are reported as mean (±95% CI). Because of an extreme outlier, the median concentrations (25th and 75th percentile) in erythropoietin over time are reported in the figure. Excluding the outlier and calculating the mean value provided a similar picture (data not shown). P, placebo; D, dapagliflozin; H, hydrochlorothiazide.

Median change in 24-h systolic blood pressure and median percentage change in plasma volume and red cell mass in substudy participating subjects in the placebo, dapagliflozin and hydrochlorothiazide groups. Because of the small sample size, data are reported as median (25th and 75th percentile) in order to exclude the influence of few extreme values that drive mean changes. In two patients plasma volume change could not be measured because an end of study measurement was not available. As a result, the sample size was too small to show 2.5–97.5% percentile. P, placebo; D, dapagliflozin; H, hydrochlorothiazide.